Tetrahydro-1,3,4,6-tetramethylimidazo(4,5-d)imidazole-2,5(1H,3H)-dione

CAS : 10095-06-4

Ref. 3D-FT03757

Informations sur le produit

• Nom: Tetrahydro-1,3,4,6-tetramethylimidazo(4,5-d)imidazole-2,5(1H,3H)-dione
• Synonymes: 1,3,4,6-Tetramethyl-3A,6A-dihydroimidazo[4,5-D]imidazole-2 ,5-quinoneTetrahydro-1,3,4,6-tetramethylimidazo(4,5-D)imidazole-2,5(1H ,3H)-dione, 1,3,4,6-Tetramethyl-3a,6a-dihydroimidazo[4,5-d]imidazole-2,5-dione, 1,3,4,6-Tetramethyl-tetrahydro-imidazo[4,5-d]imidazole-2,5-dione, 1,3,4,6-tetramethyltetrahydroimidazo[4,5-d]imidazole-2,5(1H,3H)-dione, 2,4,6,8-Tetramethyl-2,4,6,8-tetraazabicyclo[3.3.0]-3,7-oxandione, Glycoluril, 1,3,4,6-tetramethyl-, Imidazo[4,5-d]imidazole-2,5(1H,3H)-dione, tetrahydro-1,3,4,6-tetramethyl-, Mebicar, Tetrahydro-1,3,4,6-tetramethylimidazo[4,5-d]imidazole-2,5(1H,3H)-dione, Mebikar

Description

Tetrahydro-1,3,4,6-tetramethylimidazo(4,5-d)imidazole-2,5(1H,3H)-dione (DMTI) is a phosphotungstic acid analog that has been shown to have potent synergic activity with pharmacological agents used in the treatment of congestive heart failure. It increases ATP production in cells by inhibiting the enzyme pyruvate dehydrogenase kinase and stimulating protein kinase C. DMTI also has an effect on energy metabolism by increasing the concentration of adenosine monophosphate (AMP) and decreasing the concentration of adenosine triphosphate (ATP). DMTI is a chiral compound that contains two asymmetric carbon atoms. The molecule itself is not biologically active but must be metabolized to produce the active form. This compound has a high affinity for oxytocin receptors and can be used to induce

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 198.22 g/mol
• Formule: C₈H₁₄N₄O₂
• Degré de pureté: Min. 95 Area-%
• Couleur/Forme: Powder
• InChI: InChI=1S/C8H14N4O2/c1-9-5-6(11(3)7(9)13)12(4)8(14)10(5)2/h5-6H,1-4H3
• Code InChI: InChIKey=XIUUSFJTJXFNGH-UHFFFAOYSA-N
• SMILES: CN1C(=O)N(C)C2C1N(C)C(=O)N2C